5248042025-10-012025-12-315248042025-04-012025-12-315248042025-10-012025-12-31in-capmkt:OtherExpenses1Member5248042025-04-012025-12-31in-capmkt:OtherExpenses1Member5248042025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15248042025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524804AUROPHARMANOTLISTEDINE406A01037AUROBINDO PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-092026-01-30INRMillionsQuarterlyThird quarterSingle segmentPharmaceutical products2026-02-0916:30:002026-02-0918:30:00Not applicablefalsefalseNo default.2025-10-012025-12-31UnauditedStandalone2747280000013015000002877430000014025500000201500000-135990000029110000004843000007192000003799900000207815000007992800000-17380000078190000002029700000-3140000019983000000582070000000005820700000-119000005808800000580800000110.0210.020010.0210.02Notes: <BR> 1.The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <BR> <BR> 2.The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on February 9, 2026. The results for the quarter and nine months ended December 31, 2025 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2025. <BR> <BR> 3.The Company operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment". <BR> <BR> 4.On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability (arising out of past service cost) and increase in leave liability aggregating Rs.173.8 million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount under “Exceptional Items” in the Standalone Statement of Profit and Loss for the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits. <BR> 2025-04-012025-12-31UnauditedStandalone838517000003734400000875861000003986720000056680000037600000868440000016588000002134300000115905000006453960000023046500000-173800000228727000005648700000-17000005647000000017225700000000017225700000-2540000017200300000580800000129.6629.660029.6629.66Other Expenses3799900000Other Expenses11590500000Re-measurement of defined benefit liability-15900000-15900000Re-measurement of defined benefit liability-33900000-33900000-4000000-8500000-11900000-25400000